Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > MICA


Brief Information

Name:MHC class I polypeptide-related sequence A
Target Synonym:
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 1 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data


Immobilized Human NKG2D, His Tag (Cat. No. NKD-H5245) at 2 μg/mL (100 μL/well) can bind Human MICA (24-202) Protein, Llama IgG2b Fc Tag (Cat. No. MIA-H5256) with a linear range of 0.1-2 ng/mL (QC tested).

MICA MALS images

The purity of Human MICA (24-202) Protein, Llama IgG2b Fc Tag (Cat. No. MIA-H5256) is more than 85% and the molecular weight of this protein is around 100-125 kDa verified by SEC-MALS.

Synonym Name



MHC class I polypeptide-related sequence A (MICA) belongs to the MHC class I family and MIC subfamily. MICA contains one Ig-like C1-type (immunoglobulin-like) domain. Unlike classical MHC class I molecules, MICA does not form a heterodimer with beta-2-microglobulin. MICA acts as a stress-induced self-antigen that is recognized by gamma delta T-cells. MICA is ligand for the KLRK1/NKG2D receptor. MICA bind to KLRK1 leads to cell lysis.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CLN-619 CLN-619 Phase 1 Clinical PDI Therapeutics Inc Solid tumours Details
FT-536 FT-536 Phase 1 Clinical Fate Therapeutics Inc Solid tumours Details
α3 MICA/B iNK cells (GT Biopharma/Fate Therapeutics) Gt Biopharma Inc, Fate Therapeutics Inc Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message